

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

BMJ Open

BMJ Open

Early Impact of COVID-19 on Use of Connected Digital Products in Clinical Research

Journal:	BMJ Open
Manuscript ID	bmjopen-2020-047341
Article Type:	Original research
Date Submitted by the Author:	09-Dec-2020
Complete List of Authors:	Marra, Caroline; Harvard Business School Gordon, Willam; Brigham and Women's Hospital Department of Medicine; Massachusetts General Hospital Stern, Ariel; Harvard Business School, Technology and Operations Management
Keywords:	COVID-19, Clinical trials < THERAPEUTICS, Telemedicine < BIOTECHNOLOGY & BIOINFORMATICS
	·

SCHOLARONE[™] Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

reliez oni

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Early Impact of COVID-19 on Use of Connected Digital Products in Clinical Research

Caroline Marra, Harvard Business School, Boston, MA

William J Gordon, Division of General Internal Medicine, Brigham and Women's Hospital, Boston MA, Department of Biomedical Informatics, Harvard Medical School, Boston, MA, Mass General Brigham, Boston, MA

Ariel D Stern, Harvard Business School, Boston, MA, Harvard-MIT Center for Regulatory Science, Boston, MA

Correspondence to: Ariel D. Stern, astern@hbs.edu

Structured Abstract

Objectives: In an effort to mitigate COVID-19 related challenges for clinical research, the US FDA issued new guidance for the conduct of "virtual" clinical trials in March 2020. This study documents trends in the use of connected digital products (CDPs), tools that enable remote patient monitoring and telehealth consultation, in clinical trials before and after the onset of the pandemic.

Design: We applied a comprehensive text search algorithm to clinical trial registry data to identify trials that use CDPs for remote monitoring or telehealth. We compared CDP use in the months before and after the issuance of FDA guidance facilitating virtual clinical trials.

Setting: All trials registered on ClinicalTrials.gov with start dates from October 1, 2019 to September 30, 2020.

Outcome measures: The primary outcome measure was the overall percentage of CDP use in clinical trials started in the five months prior to the pandemic onset (Oct 2019-Feb 2020) compared to the five months following (May-Sep 2020). Secondary outcome measures included CDP usage by trial type (interventional, observational), funder type (industry, non-industry), and diagnoses (COVID-19 or non-COVID-19 participants).

Results: CDP usage in clinical trials increased by only one percentage point, from 14.4% (n=11,458) of all trials initiated in the five months prior to the pandemic onset to 15.4% (n=12,863) of those started in the five months following (p=0.02). There was a more notable increase in CDP usage among observational studies and non-industry funded trials, and the increase among these was driven entirely by CDP use in trials related to COVID-19.

Conclusions: These findings suggest that new options created by regulatory guidance to stimulate telehealth and remote monitoring have yet to be widely incorporated into clinical research. Thus far, CDPs adoption has increased primarily in observational studies where virtual protocols are medically necessary due to the participants' COVID-19 diagnosis.

BMJ Open

Strength & Limitations of This Study

- This study is the first to quantify post-pandemic trends in the use of telehealth and remote patient monitoring within the clinical research setting.
- A comprehensive text search algorithm was used to identify telehealth and remote monitoring use in clinical trials that started before and after the FDA issued "virtual" protocol guidance to mitigate pandemic-related challenges with in-person research.
- The results suggest that regulatory policy updates have not yet led to a dramatic increase in take-up of remote monitoring and telehealth in clinical research.
- The short post-period analysis window (trials started in the five month period from May-Sep 2020) precludes the ability to draw implications for the pandemic's longer-term impact on the conduct of clinical research.

Il rescu

Introduction

When the World Health Organization declared COVID-19 a global pandemic in March 2020, many aspects of health care were rapidly upended including the traditional conduct of clinical research. Preliminary evidence has documented the suspension of critical clinical trials and postponement of new trial start dates due to enrollment challenges and site closures. ^{1,2,3}

In an effort to keep clinical research moving forward at a time when visits to in-person sites were challenging and risky, the FDA issued new, comprehensive guidance for the conduct of clinical trials, with the aim of encouraging virtual patient consultations and remote collection of clinical outcomes assessments.⁴

Connected digital products (CDPs) are portable, software and sensor-based technologies that are designed for patient use with little to no clinician involvement. These products enable remote monitoring and virtual consultation in the clinical research setting. A dramatic increase in the use of such products in clinical trials has been documented in the years prior to COVID-19.⁵ Though the appeal of CDPs is clear^{6,7} – both for the pandemic duration and beyond – evidence describing their adoption in clinical research initiated following COVID-19 onset is lacking.

In an effort to understand recent implementation of remote monitoring and telehealth in clinical research, this study documents trends in the use of connected digital products in clinical trials that launched before and after the emergence of pandemic-related challenges for traditional protocols. Trends in CDP adoption data are particularly relevant given the latest FDA guidance for clinical trials and broader telehealth-related policy changes, such as the rapid movement of payers to cover a broad range of virtual care delivery services.⁸

BMJ Open

Methods

We applied a text search algorithm to trial records downloaded from ClinicalTrials.gov to identify trials that used CDPs.⁹ ClinicalTrials.gov is a publicly-available database that is considered comprehensive, as trial registration is required (1) when a study is being used to support the regulatory approval of a new therapeutic product and (2) when it is intended for publication in one of the International Committee of Medical Journal Editors' member journals.^{10,11} To conduct the search, we adapted the set of CDP search terms published in Marra et al. 2020⁵ to include terms specific to remote monitoring and telehealth delivery [**Supplementary File** includes the list of search terms]. We validated our search protocol with a manual review of 450 randomly selected trials [**Table 1** includes examples of qualified CDP trials].

CDP search term(s)	Trial Type	Trial Summary	Clinical- Trials.gov Identifier
Fitbit, video- conferencing	Pre-period, Interventional, Non- Industry	Hospital-sponsored, phase 4 trial to determine whether an approved drug for attention deficit can help patients with mild cognitive impairment. Fitbit Charge 3 is used to continuously monitor sleep and activity. All visits occur over videoconferencing .	NCT03811847
Home-based pulse oximeter, virtual care platform	Post-period, COVID, Interventional, Non-Industry	Canadian research institute-led trial to demonstrate effectiveness & efficacy of a virtual care model for COVID-19 patients in home isolation. Patients are given a home-based pulse oximeter and access to a virtual care platform (VIRUTES).	NCT04420182
Apple watch	Post-period, Non- COVID, Interventional, Non- Industry	University-sponsored interventional trial testing whether a novel intervention reduces early reoccurrence of atrial fibrillation after catheter-based ablation.	NCT04433091

Table 1: Examples of Connected Digital Product Usage Identified in Clinical Trials

		Uses Apple Watch worn continuously by participants to measure and record ECG data for the primary endpoint.	
Telemedicine, eDiary	Post-Period, Non- COVID, Interventional, Industry	Pfizer-led phase 2a proof of concept study evaluating the efficacy and safety of crisaborole in adults with stasis dermatitis. Uses a de-centralized trial design involving remote contact by telemedicine and an eDiary for participant data collection.	NCT04091087
Televisit	Post-period, Non- COVID Interventional, Non- Industry	VA-sponsored interventional trial evaluating the effect of a pharmacist led medication management intervention on improving medication use for elderly patients with complex medication routines. Interactions occur via televisit .	NCT04340570

Source: ClinicalTrials.gov

Our sample period includes trials with start dates between October 1, 2019 and September 30, 2020. We divided the first five months into pre-pandemic onset ("pre-period") and the last five months into post-pandemic onset ("post-period"). We excluded trials with start dates in March and April of 2020, as FDA guidance on the conduct of clinical trials and other policies encouraging telehealth use were introduced during this time, and trial sponsors required this window to make minor protocol adjustments in response to new policies [**Table 2** presents a brief timeline of key events]. For analysis purposes, trials were segmented into COVID or non-COVID trials based on diagnoses listed in the "conditions" field. Trial type (observational or interventional) and funder type (industry or non-industry) were collected from standardized ClinicalTrials.gov fields associated with each trial.¹² Proportions of connected trials by group were compared using two-sided proportion tests. The analysis was conducted using STATA version 15.

Table 2: Timeline of selected COVID-19 related regulatory guidance and policy changes encouraging the use of telehealth and remote monitoring in the United States

	Policy/Event Name	Description
Mar 11	WHO declares COVID-19 a	a pandemic ¹
Mar 16	Emergency declarations issued in every US state ²	Acting under emergency orders, many state governors enact stay- at-home orders requiring individuals to remain in their residence, shutting down non-essential in-person commerce, and requiring postponement of elective medical procedures.
Mar 17 (revised Apr 30, Jun 25)	COVID-19 Emergency Declaration Blanket Waivers for Health Care Providers ³	CMS issues temporary emergency order to expand Medicare coverage of telehealth services provided by licensed providers, including doctors, nurse practitioners, and physician assistants.
Mar 20 (revised Jun 5)	Enforcement Policy for Non-Invasive Remote Monitoring Devices Used to Support Patient Monitoring During the COVID-19 Public Health Emergency ⁴	FDA releases first guidance for industry and FDA staff encouraging the use of certain non-invasive remote monitoring devices to support patient monitoring during COVID-19 by suggesting the agency will not object to limited modifications to the indications, claims, functionality, or hardware or software.
(revised Jul 2, Sep 21)Conduct of Clinical Trials of Medical Products during COVID-19 Publicinstitutional review boards on conduct of clinical trial suggesting trial sponsors consider using telephone an consultation in clinical trials to replace in-person site and collect clinical outcome assessments remotely us		FDA releases first guidance for industry, investigators, and institutional review boards on conduct of clinical trials, suggesting trial sponsors consider using telephone and video consultation in clinical trials to replace in-person site visits and collect clinical outcome assessments remotely using validated technology when appropriate.
Apr 30 – May 15	"Stay at home" orders lifted for most US states ⁶	Majority of states lift their "stay at home" orders but encourage individuals to limit unnecessary trips outside the home. Phased
		reopening begins and varies by state.
020]. Avai meline. 2. cited 20 Oc olicy-actio are Provid vailable fir aivers.pdf atient Mor Revised) [1 . FDA Gui mergency:	ilable from: https://www.who State Data and Policy Action et 2020]. Available from: http ons-to-address-coronavirus/. 3 lers [Internet]. Centers for Me rom: https://www.ems.gov/fii 5 . 4 . Enforcement Policy for N nitoring During the Coronavir Internet]. FDA.gov. 2020 Jun idance on Conduct of Clinical : Guidance for Industry, Invest	reopening begins and varies by state. P response [Internet]. World Health Organization. [cited 19 Oct .int/emergencies/diseases/novel-coronavirus-2019/interactive- s to Address Coronavirus [Internet]. Kaiser Family Foundation. s://www.kff.org/coronavirus-covid-19/issue-brief/state-data-and- .COVID-19 Emergency Declaration Blanket Waivers for Health edicare & Medicaid Services . 2020 Mar 17, revised 2020 Jun 25. les/document/summary-covid-19-emergency-declaration- Ion-Invasive Remote Monitoring Devices Used to Support us Disease 2019 (COVID-19) Public Health Emergency . Available from: https://www.fda.gov/media/136290/download. . Trials of Medical Products during COVID-19 Public Health estigators, and Institutional Review Boards [Internet]. FDA.gov. fda.gov/media/136238/download. 6. Moreland A, Herlihy C,

Population Movement — United States, March 1–May 31, 2020. MMWR Morb Mortal Wkly Rep 2020;69:1198–1203. Available from: https://www.cdc.gov/mmwr/volumes/69/wr/mm6935a2.htm

55
56
57
58
59
60

No patients or public were involved in this research.

Results

Over the 12-month period from October 2019 - September 2020, the overall use of CDPs in clinical trials remained relatively stable, accounting for between 12-16% of all newly started trials each month. Trials using CDPs accounted for 14.4% of all studies (1,645/11,458) in the pre-period and 15.4% (1,984/12,863) in the post-period (p=0.02). Among trials labeled as observational, there was an increase in trials using CDPs from 11.4% (312/2,731) pre-period to 15.3% (464/3,032) post-period (p<0.0001). There was also an increase in the percentage of trials using CPDs among studies funded by non-industry parties, such as hospitals, academic institutions, and government (16.3% to 18.1%, p<0.0001). The use of CDPs in industry-funded trials was notably lower than the sample average both before and after the FDA's guidance was issued in response to the pandemic onset (8.3% vs. 8.0%, p=0.67). [Figure 1].

When trials with start dates in the post-period were segmented into COVID (n=1,989) and non-COVID (n=10,874) diagnoses, the use of CDPs was higher than the pre-period average in COVID-specific trials (19.1% vs. 14.4%, p=<0.001) but not in trials unrelated to COVID-19 (14.8% vs. 14.4%, p=0.4). As such, the observed increase in CDP usage among observational and non-industry funded trials was driven by studies related directly to COVID-19. In the post-period there were no meaningful changes in use of CDPs in trials unrelated to COVID-19 ("non-COVID") [Figure 2].

As a robustness check, we removed trials where the recruitment status suggested that the study had not begun recruiting participants even though the start date had technically passed.¹³

BMJ Open

Within the subset of trials where commencement of enrollment had been confirmed (n=9,249 pre-period, 7,463 post-period), there was no difference in overall CPD usage between the preperiod and post-period (14.9% to 14.4%, p=0.41). Differences related to observational and COVID-specific trials were similar to those observed in the overall sample.

Discussion

Overall, the use of CDPs in clinical trials has increased only very modestly in trials with start dates occurring after COVID-19 was declared a global pandemic. This finding is surprising in light of new regulatory guidance introduced in late March 2020 aimed at bolstering the use of CDPs to sustain clinical research, and stands in contrast to the dramatic documented increases in the use of telemedicine for routine health care delivery over the same period of time.¹⁴ Though it may still be too early to observe the full effect of new regulatory initiatives, our findings suggest that the growing enthusiasm for telehealth in mitigating pandemic-related health care challenges has yet to be realized in the clinical research setting.

On one hand, the increase in CDP usage documented among observational trials suggests the relative ease of incorporating new remote monitoring technology into studies that do not evaluate therapeutic benefit. On the other hand, the consistently low adoption of CDPs by industry funders reinforces that firms may continue to perceive substantial risk associated with reliance on technology for trials that require regulatory review or may be reluctant to augment trial protocols and operations – even after the FDA explicitly encouraged protocol modifications to enable virtual trials. Additionally, the fact that COVID-specific trials drove the increase in CDP usage among observational and non-industry funded studies suggests that the changes in FDA guidance may have only impacted trials where virtual protocols were most necessary for the health and safety of clinicians and other patients (given the trial participants' diagnosis).

BMJ Open

Further, robustness checks find no increase in CPD usage among the subset of trials where commencement of participant recruitment has been confirmed, suggesting that the very small overall increase in CDP usage may be attributable to trials that were planned to start within the post-period analysis window (May 1-Sep 30, 2020) but may have experienced delays.

The study's primary limitation is its short analysis period. The trends identified are only representative of CDP usage in the months immediately following issuance of the FDA's guidance for conducting virtual protocols (May-Sep 2020) and implications for long term trends cannot yet be drawn. Other limitations include reliance on data entered by trial sponsors and a risk of incomplete data since trials can be retrospectively registered after their start date. We have attempted to mitigate the latter issue by waiting three weeks beyond the analysis period to download records from ClinicalTrials.gov.

Conclusion

Though the pandemic may lead to sustained changes in how health care is delivered, the longer term implications for the use of connected technology in clinical research are less clear. Despite FDA guidance encouraging remote monitoring and telehealth use in clinical trials, we did not find a meaningful increase in the usage of CDPs in trials started after the pandemic onset. Trends in the use of CDPs will be important to monitor as COVID-19 continues to impact investigators' ability to conduct clinical research and further policies around telehealth are introduced.

BMJ Open

Figure Legends/Captions

Figure 1: Proportion of Clinical Trials Started Monthly that Use Connected Digital Products for Telehealth Delivery or Remote Monitoring

The analysis time period is divided into a pre-period, which includes the five months before the pandemic onset, and a post-period, including the five months following the onset. March and April 2020 are excluded, as policy changes and guidance documents were issued during this period. Percentages on the left and right represent the average percentage of trials using connected digital products during the pre- and post-period, respectively. Asterisks indicate statistical significance in the mean difference between the pre- and post-periods using two-sided proportion tests.

Figure 2: Proportion of Clinical Trials Started that Use Connected Digital Products for Telehealth Delivery or Remote Monitoring, by Study Type & Funder Type

The "pre-period" refers to the five months prior to the pandemic onset and the "post-period" to the five months following onset. March and April 2020 are excluded, as policy changes and guidance documents were issued during this period. Trials commencing in the post-period are divided into "COVID" trials and "non-COVID" trials based on their diagnoses in the ClinicalTrials.gov conditions label. Asterisks indicate statistical significance in the mean difference between the pre- and post-periods using two-sided proportion tests.

Contributors: The study was designed by CM and ADS. CM conducted the analysis in consultation with ADS and WJG. All authors contributed to the writing of the manuscript. Lila Kelso and Melissa Ouellet provided excellent research assistance.

Data sharing: At the time of publication, the authors will share data from the study on the public GitHub repository https://github.com/arieldora/Covid19digitaltrials managed by ADS.

Ethical Approval: Not required since this was a study of publicly available information.

Competing interest: The authors declare no competing interests.

Funding: WJG acknowledges research funding from IBM and consulting income from the Office of the National Coordinator for Health Information Technology, both unrelated to this topic. ADS acknowledges research funding from the Kauffman Junior Faculty Fellowship and acknowledges consulting income from the U.S. Department of Health and Human Services unrelated to this topic.

References

¹Upadhaya S, Yu JX, Oliva C, Hooton M, Hodge J, Hubbard-Lucey VM. Impact of COVID-19 on oncology clinical trials. Nature Reviews Drug Discovery. 2020 May 18;19(6):376–7.

²Re-Envisioning Clinical Trials During The COVID-19 Pandemic [Internet]. Health Affairs Blog. [cited 2020 Oct 21]. Available from: /do/10.1377/hblog20200702.963588/full.

³Ledford H. Coronavirus shuts down trials of drugs for multiple other diseases. Nature. 2020 Mar 25;580(7801):15–6.

⁴ FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency. [Internet]. 2020 Mar. Available from: https://www.fda.gov/media/136238/download

⁵ Marra C, Chen JL, Coravos A, Stern AD. Quantifying the use of connected digital products in clinical research. npj Digital Medicine. 2020 Apr 3;3(1):1–5.

⁶ Inan OT, Tenaerts P, Prindiville SA, Reynolds HR, Dizon DS, Cooper-Arnold K, et al. Digitizing clinical trials. npj Digital Medicine. 2020 Jul 31;3(1):1–7.

⁷ Erridge S, Majeed A, Sodergren M. Virtual trials: looking beyond covid-19 [Internet]. the bmj opinion. 2020 Jul 06. [cited 2020 Nov 06]. Available from: https://blogs.bmj.com/bmj/2020/07/06/virtual-trials-looking-beyond-covid-19/

⁸ COVID-19 Emergency Declaration Blanket Waivers for Health Care Providers [Internet]. Centers for Medicare & Medicaid Services. [accessed 2020 Aug 24]. Available from: https://www.cms.gov/files/document/summary-covid-19-emergency-declaration-waivers.pdf

9 Download AACT Database. Clinical Trials Transformation Initiative. [downloaded on 2020 October 21]. Available from: <u>https://aact.ctti-clinicaltrials.org/</u>

¹⁰ 121 STAT. 904 PUBLIC LAW 110-85--SEPT. 27, 2007 [Internet]. Available from: https://www.govinfo.gov/content/pkg/PLAW-110publ85/pdf/PLAW-110publ85.pdf#page=82


¹¹Clinical Trials [Internet]. International Committee of Medical Journal Editors. [cited 2020 Oct 21]. Available from: <u>http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html</u>

¹² Glossary of Common Site Terms [Internet]. ClinicalTrials.gov. [cited 2020 Oct 21]. Available from: https://clinicaltrials.gov/ct2/about-studies/glossary


¹³ Recruitment Status Description [Internet]. ClinicalTrials.gov. [accessed 2020 Oct 21]. <u>https://clinicaltrials.gov/ct2/help/glossary/recruitment-status</u>. **BMJ** Open

¹⁴ Seema Verma. Early Impact of CMS Expansion of Medicare Telehealth During COVID-19
 [Internet]. Health Affairs Blog. 2020 [cited 2020 Oct 21]. Available from:
 /do/10.1377/hblog20200715.454789/full

tor peer terien only



and post-periods using two-sided proportion tests. **Source**: Authors' analysis of ClinicalTrials.gov data.



Notes: The "pre-period" refers to the five months prior to the pandemic onset and the "post-period" to the five months following onset. March and April 2020 are excluded, as policy changes and guidance documents were issued during this period. Trials commencing in the post-period are divided into "COVID" trials and "non-COVID" trials based on their diagnoses in the ClinicalTrials.gov conditions label. Asterisks indicate statistical significance in the mean difference between the pre- and post-periods using two-sided proportion tests. **Source**: Authors' analysis of ClinicalTrials.gov data

4 5 6

7 8

9 10 11

12 13

14 15

16 17

18 19

20 21

22 23

24 25

31 32

33 34

35 36

41 42 43

44 45

46

47 48

49 50

51

52 53

54 55

56 57 58

59

60

BMJ Open

Supplementary Materials

Additional Details on Methods Used to Create and Validate Search Term Algorithm for **Identification of Connected Digital Products**

Below is the complete set of the 140 search terms adapted from the list used in Marra, et al. 2020 to include additional terms related to telehealth delivery. These terms were used to identify a clinical trial as using a connected digital product (CDP). The research team used an automated algorithm to search for each term in several relevant ClinicalTrials.gov fields, such as "official title", "brief summary", "detailed description", "interventions", "study arms", and "outcome measures." To confirm accuracy of the search algorithm, a random number generator was used to select 450 trials that were flagged for manual review. Of the 450 reviewed, 3 false positives were found, suggesting sensitivity of our search algorithm to be ~99%. There were no false negatives.

To alleviate incomplete data concerns arising from trial registration delays, we downloaded ClinicalTrials.gov records with trial start dates occurring between Oct 1, 2019 through Sep 30, 2020 from https://aact.ctti-clinicaltrials.org/ on October 21, 2020, allowing 3 weeks for trial sponsors to retroactively register studies. 20/1

Search Term List:

1. accuchek 2. actigraph 3. activity monitor 4. aim covid-19 app 5. amazon alexa app-based practice 6. 7. apple watch

awareness bracelet

8.

9.	biosensor	17.
10.	biovitals	18.
11.	brave program	19.
12.	cct game	20.
13.	chat-based support	21.
14.	collected online	22.
15.	conducted entirely online	23.
16.	continuous glucose monitor	24.

- 17. covid-19 symptom tracker
- 18. dexcom

- 19. digital app
- 20. digital biomarker
- 21. digital camera
- 22. digital cardiac counseling
 - digital counseling
 - digital data collection

BMJ Open

25.	digital therapeutic	57.	miro	87.	post online
26.	digital video camera	58.	mobile app	88.	qualtrics
27.	e-learning	59.	mobile device	89.	redcap
28.	electronic data collection	60.	movehero	90.	reminder bracelet
29.	electronic patient journal	61.	ncapp	91.	remote assessment
30.	electronic questionnaire	62.	newsfeed	92.	remote consultation
31.	exercise bracelet	63.	non-contact ecg	93.	remote mindfulness session
32.	facebook	64.	online class	94.	remote monitoring
33.	fall risk bracelet	65.	online coaching	95.	secure electronic ecrf
34.	fitbit	66.	online contact	96.	skype
35.	freestyle libre	67.	online daily diary	97.	sleep sense
36.	gamification	68.	online exercise	98.	smart bracelet
37.	garmin	69.	online fall detection system	99.	smart care vip bracelet
38.	google	70.	on-line forum	100.	smartpill
39.	handheld manometer	71.	on-line group	101.	smart tv
40.	hand-held spirometer	72.	online intervention	102.	smartphone
41.	health app	73.	online learning	103.	smartwatch
42.	hear glue ear app	74.	online meeting	104.	social media
43.	holter monitor	75.	online mindfulness	105.	stop touching your face
44.	home pulse oximeter	interven		program	
45.	hwa watch	76.	online platform	106.	study website
46.	hydration sensor	77.	online questionnaire	107.	tablet-based game
47.	i-neb	78. question	online self-administered	108.	teleconference
48.	ICOPE App	79.	online self-completed	109.	teleconsultation
49.	intelligent pulse oximeter	question		110.	telehealth
50.	internet	80.	online support	111.	telemedicine
51.	ipad	81.	online survey	112.	telephone
52.	iphone	82.	online trial	113.	telephone coaching
53.	meditation app	83.	online yoga	114.	telerehabilitation
54.	mhealth	84.	phone app	115.	text message
55.	mindfulness app	85.	phone call	116.	thermal sensor chip
56.	minimed	86.	phone interview	117.	vibrolung

2		
3	118.	video-based
4 5	119.	video call
6	120.	video chat
7 8	121.	video communication
9		
10 11	122.	video consultation
12	123.	video encounters
13 14	124.	video observation
15	125.	videoconferencing
16 17	126.	videophone call
18		virtual check-in
19	127.	
20 21	128.	virtual care at home
22	129.	virtual clinic
23 24	130.	virtual clinic virtual group intervention virtual reality virtual visit watchpat web-application websaed webex wechat whatsapp zoom
24	131.	virtual reality
26		
27 28	132.	virtual visit
29	133.	watchpat
30 31	134.	wearable
32	135.	web-application
33 34	136.	web based
35	137.	webex
36 37		
38	138.	wechat
39	139.	whatsapp
40 41	140.	zoom
41 42		
43		

BMJ Open

BMJ Open

The use of connected digital products in clinical research following the COVID-19 pandemic: a comprehensive analysis of clinical trials

Journal:	BMJ Open	
Manuscript ID	bmjopen-2020-047341.R1	
Article Type:	Original research	
Date Submitted by the Author:	22-Apr-2021	
Complete List of Authors:	Marra, Caroline; Harvard Business School Gordon, William; Brigham and Women's Hospital Department of Medicine; Harvard Medical School Stern, Ariel; Harvard Business School, Technology and Operations Management	
Primary Subject Heading :	Research methods	
Secondary Subject Heading:	Health economics, Health informatics, Pharmacology and therapeutics, Research methods, Health services research	
Keywords:	COVID-19, Clinical trials < THERAPEUTICS, Telemedicine < BIOTECHNOLOGY & BIOINFORMATICS, Information technology < BIOTECHNOLOGY & BIOINFORMATICS, GENERAL MEDICINE (see Internal Medicine), HEALTH ECONOMICS	

SCHOLARONE[™] Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

reliez oni

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

The use of connected digital products in clinical research following the COVID-19 pandemic: a comprehensive analysis of clinical trials

Caroline Marra, Harvard Business School, Boston, MA

William J Gordon, Division of General Internal Medicine, Brigham and Women's Hospital, Boston MA, Department of Biomedical Informatics, Harvard Medical School, Boston, MA, Mass General Brigham, Boston, MA

Ariel D Stern, Harvard Business School, Boston, MA, Harvard-MIT Center for Regulatory Science, Boston, MA

Correspondence to: Ariel D. Stern, astern@hbs.edu

Structured Abstract

Objectives: In an effort to mitigate COVID-19 related challenges for clinical research, the U.S. FDA issued new guidance for the conduct of "virtual" clinical trials in late March 2020. This study documents trends in the use of connected digital products (CDPs), tools that enable remote patient monitoring and telehealth consultation, in clinical trials both before and after the onset of the pandemic.

Design: We applied a comprehensive text search algorithm to clinical trial registry data to identify trials that use CDPs for remote monitoring or telehealth. We compared CDP use in the months before and after the issuance of FDA guidance facilitating virtual clinical trials.

Setting: All trials registered on ClinicalTrials.gov with start dates from May 2019 through February 2021.

Outcome measures: The primary outcome measure was the overall percentage of CDP use in clinical trials started in the ten months prior to the pandemic onset (May 2019-Febrary 2020) compared to the ten months following (May 2020-February 2021). Secondary outcome measures included CDP usage by trial type (interventional, observational), funder type (industry, non-industry), and diagnoses (COVID-19 or non-COVID-19 participants).

Results: CDP usage in clinical trials increased by only 1.65 percentage points, from 14.19% (n=23,473) of all trials initiated in the ten months prior to the pandemic onset to 15.84% (n=26,009) of those started in the ten months following (p<0.01). The increase occurred primarily in observational studies and non-industry funded trials and was driven entirely by CDP usage in trials for COVID-19.

Conclusions: These findings suggest that in the short-term, new options created by regulatory guidance to stimulate telehealth and remote monitoring were not widely incorporated into clinical research. In the months immediately following the pandemic onset, CDP adoption increased primarily in observational and non-industry funded studies where virtual protocols are likely medically necessary due to the participants' COVID-19 diagnosis.

Strength & Limitations of This Study

- This study is the first to quantify post-pandemic trends in the use of telehealth and remote patient monitoring technology within the clinical research setting.
- A comprehensive text search algorithm was created and used to identify telehealth and remote monitoring use in clinical trials.
- Detailed, manual review of 500 trial records validated the search term list and algorithm, confirming a high degree of sensitivity and specificity.
- The limited post-period analysis window (10 months) precludes the ability to draw implications for the pandemic's longer-term impact on the conduct of clinical research.
- The identification of CDPs in clinical trials is dependent on the trial sponsor entering information about remote monitoring and/or telehealth delivery when creating or updating the ClinicalTrials.gov record.

Introduction

 When the World Health Organization declared COVID-19 a global pandemic in March 2020, many aspects of health care were rapidly upended including the traditional conduct of clinical research. Preliminary evidence has documented the suspension of critical clinical trials and postponement of new trial start dates due to enrollment challenges and site closures. ^{1,2,3} In an effort to keep clinical research moving forward at a time when visits to in-person sites were challenging and risky, the United States Food and Drug Administration (FDA) issued new, comprehensive guidance for the conduct of clinical trials, with the aim of encouraging virtual patient consultations and remote collection of clinical outcomes assessments.⁴

Connected digital products (CDPs) are portable software and sensor-based technologies that are designed for patient use with little to no clinician involvement. These products collect health-related measurements from patients and thus enable remote monitoring and virtual consultation in the clinical research setting. Examples of CDPs include wearable activity trackers and heart rate monitors, mobile apps used for data delivery and collection, ingestible sensors, and health assessments conducted via a mobile platform. ⁵ In the years prior to COVID-19, a dramatic increase in the use of CDPs has been documented in clinical trials.⁵ Though the appeal of CDPs is clear^{6,7} – both for the pandemic duration and beyond – evidence describing their adoption in the clinical research setting following COVID-19 is lacking.

In an effort to understand recent implementation of remote monitoring and telehealth in clinical research, this study asks whether CDP use in clinical trials increased following the FDA's March 2020 issuance of guidance for the conduct of virtual trials. The study documents trends in the use of connected digital products in clinical trials that started both before and after the emergence of pandemic-related challenges for traditional protocols. Trends in CDP adoption

Page 5 of 21

BMJ Open

data within the clinical research setting are particularly relevant in light of the pandemic-induced
broader telehealth-related policy changes, such as the rapid movement of payers to cover a broad
range of virtual care delivery services and particular generosity in the coverage of remote patient
monitoring technologies.^{8,9}

Methods

We applied a text search algorithm to the full set of trial records downloaded from ClinicalTrials.gov to identify trials that used CDPs.¹⁰ ClinicalTrials.gov is a publicly-available database that is considered comprehensive, as trial registration is required (1) when a study is being used to support the regulatory approval of a new therapeutic product and (2) when it is intended for publication in one of the International Committee of Medical Journal Editors' member journals.^{11,12} To conduct the search, we adapted the set of CDP search terms published in Marra et al. 2020⁵ to include additional terms specific to remote monitoring and telehealth delivery [**Supplementary File** includes the list of search terms]. We used an automated algorithm to search for each term in several relevant ClinicalTrials.gov fields, such as "official title", "brief summary", "detailed description", "interventions", "study arms", and "outcome measures." We validated our search protocol with a manual review of 500 randomly selected trials [**Table 1** includes examples of qualified CDP trials].

CDP search term(s)	Trial Type	Trial Summary	Clinical- Trials.gov Identifier
Fitbit, video- conferencing	Pre-period, Non- COVID, Interventional, Non- Industry	Hospital-sponsored, phase 4 trial to determine whether an approved drug for attention deficit can help patients with mild cognitive impairment. Fitbit Charge 3 is used to continuously monitor sleep and activity. All visits occur over videoconferencing.	NCT0381184
Home-based pulse oximeter, virtual care platform	Post-period, COVID, Interventional, Non-Industry	Canadian research institute-led trial to demonstrate effectiveness & efficacy of a virtual care model for COVID-19 patients in home isolation. Patients are given a home-based pulse oximeter and access to a virtual care platform (VIRUTES).	NCT04420182
Apple watch	Post-period, Non- COVID, Interventional, Non- Industry	University-sponsored interventional trial testing whether a novel intervention reduces early reoccurrence of atrial fibrillation after catheter-based ablation. Uses Apple Watch worn continuously by participants to measure and record ECG data for the primary endpoint.	NCT0443309
Telemedicine, eDiary	Post-Period, Non- COVID, Interventional, Industry	Pfizer-led phase 2a proof of concept study evaluating the efficacy and safety of crisaborole in adults with stasis dermatitis. Uses a de-centralized trial design involving remote contact by telemedicine and an eDiary for participant data collection.	NCT0409108'
Televisit	Post-period, Non- COVID Interventional, Non- Industry	VA-sponsored interventional trial evaluating the effect of a pharmacist led medication management intervention on improving medication use for elderly patients with complex medication routines. Interactions occur via televisit .	NCT0434057(

Table 1. Examples of Connected Digital Product Usage Identified in Clinical Trials

Source: ClinicalTrials.gov

Our sample period includes trials with start dates between May 1, 2019 and February 28,

2021. We divided the first ten months of the sample into pre-pandemic onset ("pre-period") and

BMJ Open

the last ten months of the sample into post-pandemic onset ("post-period"). We excluded trials with start dates in March and April of 2020, as FDA guidance on the conduct of clinical trials and other public policies encouraging telehealth use were introduced during this time, and trial sponsors would have needed this window to make protocol adjustments in response to new policies [**Table 2** presents a brief timeline of key events]. For analysis purposes, trials were segmented into COVID or non-COVID trials based on diagnoses listed in the "conditions" field. Trial type (observational or interventional) and funder type (industry or non-industry) were collected from standardized ClinicalTrials.gov fields associated with each trial.¹³ To test whether the proportion of trials using CPDs was statistically different in the pre-period and post-period, we performed two-sided z-tests using the means and standard deviations from the 10-month observation periods in each group. The analysis was conducted using STATA version 15.

 Table 2: Timeline of selected COVID-19 related regulatory guidance and policy changes encouraging the use of telehealth and remote monitoring in the United States

Date	Policy/Event Name	Description
Mar 11, 2020	WHO declares COVID-19 a	a pandemic ¹
Mar 16, 2020	Emergency declarations issued in every U.S. state ²	Acting under emergency orders, many state governors enact stay- at-home orders requiring individuals to remain in their residence, shutting down non-essential in-person commerce, and requiring postponement of elective medical procedures.
Mar 17, 2020 (revised Apr 30, Jun 25)	COVID-19 Emergency Declaration Blanket Waivers for Health Care Providers ³	CMS issues temporary emergency order to expand Medicare coverage of telehealth services provided by licensed providers, including doctors, nurse practitioners, and physician assistants.
Mar 20, 2020 (revised Jun 5)	Enforcement Policy for Non-Invasive Remote Monitoring Devices Used to Support Patient Monitoring During the COVID-19 Public Health Emergency ⁴	FDA releases first guidance for industry and FDA staff encouraging the use of certain non-invasive remote monitoring devices to support patient monitoring during COVID-19 by suggesting the agency will not object to limited modifications to the indications, claims, functionality, or hardware or software.

Mar 27, 2020 (revised Jul 2, Sep 21)	FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency ⁵	FDA releases first guidance for industry, investigators, and institutional review boards on conduct of clinical trials, suggesting trial sponsors consider using telephone and video consultation in clinical trials to replace in-person site visits and collect clinical outcome assessments remotely using validated technology when appropriate.
Apr 30 – May 15, 2020	"Stay at home" orders lifted for most U.S. states ⁶	Majority of states lift their "stay at home" orders but encourage individuals to limit unnecessary trips outside the home. Phased reopening begins and varies by state.
2020]. Avai <u>simeline.</u> 2. cited 20 Oc colicy-actic Care Provid Available fi waivers.pdf Patient Mon (Revised) [1 5. FDA Gui Emergency 2020 Mar. A Fynan MA, Population	lable from: https://www.who. State Data and Policy Actions et 2020]. Available from: http: ons-to-address-coronavirus/. 3 . lers [Internet]. Centers for Me rom: https://www.cms.gov/fil C 4 . Enforcement Policy for N nitoring During the Coronaviru (internet]. FDA.gov. 2020 Jun. dance on Conduct of Clinical c Guidance for Industry, Invest Available from: https://www.f et al. Timing of State and Ten Movement — United States, N	 Presponse [Internet]. World Health Organization. [cited 19 Oct int/emergencies/diseases/novel-coronavirus-2019/interactive- s to Address Coronavirus [Internet]. Kaiser Family Foundation. s://www.kff.org/coronavirus-covid-19/issue-brief/state-data-and- .COVID-19 Emergency Declaration Blanket Waivers for Health dicare & Medicaid Services . 2020 Mar 17, revised 2020 Jun 25. les/document/summary-covid-19-emergency-declaration- on-Invasive Remote Monitoring Devices Used to Support us Disease 2019 (COVID-19) Public Health Emergency Available from: https://www.fda.gov/media/136290/download. Trials of Medical Products during COVID-19 Public Health stigators, and Institutional Review Boards [Internet]. FDA.gov. Cda.gov/media/136238/download. 6. Moreland A, Herlihy C, rritorial COVID-19 Stay-at-Home Orders and Changes in March 1–May 31, 2020. MMWR Morb Mortal Wkly Rep ps://www.cdc.gov/mmwr/volumes/69/wr/mm6935a2.htm
Patient & .	Public Involvement Stateme	ent

Neither patients nor the public were involved in this research.

Results

Over the 22-month period from May 2019 - February 2021, the overall use of CDPs in clinical trials remained relatively stable, accounting for between 12-19% of all newly started trials in each month of our dataset. Trials using CDPs accounted for 14.19% (3,330/23,473) of all trials started in the pre-period and 15.84% (4,121/26,009) of trials started in the post-period. This 1.65 percentage point increase represents a small but statistically significant uptick in CPD usage for trials with start dates after the pandemic onset (p<0.01). [Figure 1].

BMJ Open

Among trials labeled as observational, there was a larger average increase in trials using CDPs from 11.7% (569/4,863) pre-period to 14.6% (799/5,490) post-period (p<0.001). There was also an increase in the percentage of trials using CPDs among studies funded by non-industry parties, such as hospitals, academic institutions, and government (16.2% to 18.3%, p<0.01). The use of CDPs in industry-funded trials was notably lower than the sample mean both before and after the FDA's guidance was issued in response to the pandemic onset (7.9% vs. 8.9%, p=0.17), although this share also experienced a small overall increase, on average.

Trials with start dates in the post-period were segmented into COVID (n=3,294) and non-COVID (n=22,715) diagnoses. Among trials conducted in COVID-19 patients, use of CDPs was significantly higher than the pre-period average (20.0% vs. 14.2%, p<0.0001). However, among trials unrelated to COVID-19 ("non-COVID") that were started in the post-period, the change in CDP usage compared to the pre-period was very small and not statistically significant (15.0% vs. 14.2%, p=0.19). As such, the observed increase in CDP usage among observational and non-industry funded trials appears to have been driven by studies related directly to COVID-19. [Figure 2].

To further validate the results, we performed a series of robustness checks. First, we removed trials where the recruitment status suggested that the study had not begun recruiting participants even though the start date had technically passed.¹⁴ Within the subset of trials where commencement of enrollment had been confirmed (n=19,785 pre-period, 18,426 post-period), there was no statistically significant difference in overall CPD usage between the pre-period and post-period (15.1% to 15.9%, p=0.38). Differences seen in observational and COVID-specific trials were similar to those observed in the overall sample. Second, we removed trials conducted outside of the United States because the guidance encouraging virtual trials was issued by the

U.S. FDA. Though we find a somewhat higher rate of CPD adoption among U.S. trials (between 15.7-24.3% per month), the average increase in CDP usage among U.S. trials following the pandemic onset was the same as the average seen for all trials in the sample (1.7 percentage points from pre-period to post-period) [Supplementary File].

Discussion

Overall, the use of CDPs in clinical trials increased only very modestly in trials with start dates occurring after COVID-19 was declared a global pandemic. This finding is surprising in light of new regulatory guidance introduced in late March 2020, which aimed to bolster the use of CDPs to sustain clinical research. Moreover, these modest increases stand in sharp contrast to the multiple-order-of-magnitude increases in the use of telemedicine for routine health care delivery that were observed over the same period of time.¹⁵ Though it may still be too early to observe the full effect of new regulatory initiatives, our findings suggest that the growing enthusiasm for telehealth and remote patient monitoring in mitigating pandemic-related health care challenges has yet to be realized in the clinical research setting.

There are several possible explanations for why CPD usage in the clinical research setting did not increase as dramatically as expected in the months following the pandemic onset. On one hand, the increase in CDP usage documented among observational trials (rather than interventional trials) suggests the relative ease of incorporating new remote monitoring technology into studies that do not evaluate therapeutic benefit. Implementation of protocol changes may be more accessible in the context of observational analysis that does not require rigorous prior planning and approval to incorporate into a study design. On the other hand, the consistently lower adoption of CDPs by industry funders reinforces that firms may continue to perceive substantial risk associated with reliance on technology for trials that require regulatory

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Page 11 of 21

BMJ Open

review or may be reluctant to augment trial protocols and operations – even after the FDA explicitly encouraged protocol modifications to enable virtual trials. Further, the extent to which FDA guidance should elicit a change in protocol design by trial sponsors should be most acutely observed in trials with U.S. sites. However, we find the same percentage point increase in CDP usage following the pandemic onset for U.S. trials as was seen in all trials. It is also possible that clinical trial investigators do not yet see value in adding CDPs to their trials or lack the technical expertise to do so, despite regulatory encouragement.

Additionally, the fact that COVID-specific trials drove the observed increase in CDP usage suggests that the changes in FDA guidance may have primarily impacted trials where virtual protocols were most necessary for the health and safety of clinicians and other patients (in this case, given the trial participants' diagnosis). Though an increase in CDP usage among non-COVID related trials may still materialize in the future, there has yet to be any evidence of massive take-up on the scale of other services, such as telemedicine. Though several factors could add to investigator and trial sponsor hesitancy in the adoption of remote monitoring and telehealth technology, the findings of this study suggest that trial sponsors may be unwilling or unable to adopt CDPs in their research design until there is either medical necessity or formalized regulatory requirements to do so.

Finally, robustness checks find a very small but non-statistically significant increase in CPD usage among the subset of trials where commencement of participant recruitment could be confirmed, suggesting that at least some of the small overall increase in CDP usage may be attributable to trials that were planned to start within the post-period analysis window (May 1, 2020 - Feb 28, 2021) but may have experienced delays.

BMJ Open

The study's primary limitation is its somewhat short analysis period. The trends identified are only representative of CDP usage in the 10 months immediately following issuance of the FDA's guidance for conducting virtual protocols (May 2020 – Feb 2021) and implications for long term trends cannot yet be drawn. Other limitations include reliance on data entered by trial sponsors and a risk of incomplete data since trials can be retrospectively registered after their start date. We have attempted to mitigate the latter issue by waiting five weeks beyond the end of the analysis period to download records from ClinicalTrials.gov.

Conclusion

Though the pandemic may lead to sustained changes in how health care is delivered, the longer term implications for the use of connected technology in clinical research are less clear. Despite regulatory guidance encouraging remote monitoring and telehealth use in clinical trials, we did not find a meaningful increase in the usage of CDPs in trials started after the pandemic onset. Trends in the use of CDPs will be important to monitor as COVID-19 continues to impact investigators' ability to conduct clinical research and further policies around telehealth are introduced.

BMJ Open

Figure Legends/Captions

Figure 1: Proportion of Clinical Trials Started Monthly that Use Connected Digital Products for Telehealth Delivery or Remote Monitoring

The Pre-Period and Post-Period analysis windows include the 10 months before and after the COVID-19 pandemic onset. Percentages on the left and right represent the average percentage of trials using connected digital products during the pre- and post-period, respectively. Asterisks indicate statistical significance in the mean difference between the pre- and post-periods using two-sided proportion tests.

Figure 2: Proportion of Clinical Trials Started that Use Connected Digital Products for Telehealth Delivery or Remote Monitoring, by Study Type & Funder Type

"Pre-period" and "Post-period" refer to the ten months immediately before and after COVID-19 onset in the U.S. March and April 2020 are excluded because policy changes and guidance documents were issued during that time. Trials started in the post-period are divided into "COVID" trials and "non-COVID" trials based on their diagnoses in the ClinicalTrials.gov conditions label. Asterisks indicate statistical significance in the mean difference between the pre- and post-periods using two-sided proportion tests.

BMJ Open

Contributors: The study was designed by CM and ADS. CM conducted the analysis in consultation with ADS and WJG. All authors contributed to the writing of the manuscript.

Data sharing: At the time of publication, the authors will share data from the study on the public GitHub repository https://github.com/arieldora/Covid19digitaltrials managed by ADS.

Ethical Approval: This study analyzes publicly available clinical trial protocols that have been registered in the freely-accessible ClinicalTrials.gov database provided by the National Library of Medicine. Neither ethical approval nor participation consent was required because no human participants or members of the public are involved.

Competing interest: The authors declare no competing interests.

Funding: WJG acknowledges research funding from IBM and consulting income from the Office of the National Coordinator for Health Information Technology, both unrelated to this topic. ADS acknowledges research funding from the Kauffman Junior Faculty Fellowship and acknowledges consulting income from the U.S. Department of Health and Human Services unrelated to this topic.

Acknowledgements: The authors would like to thank Lila Kelso and Melissa Ouellet for excellent research assistance.

References

¹Upadhaya S, Yu JX, Oliva C, Hooton M, Hodge J, Hubbard-Lucey VM. Impact of COVID-19 on oncology clinical trials. Nature Reviews Drug Discovery. 2020 May 18;19(6):376–7.

²Re-Envisioning Clinical Trials During The COVID-19 Pandemic [Internet]. Health Affairs Blog. [cited 2020 Oct 21]. Available from: /do/10.1377/hblog20200702.963588/full.

³Ledford H. Coronavirus shuts down trials of drugs for multiple other diseases. Nature. 2020 Mar 25;580(7801):15–6.

⁴ FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency. [Internet]. 2020 Mar. Available from: https://www.fda.gov/media/136238/download

⁵ Marra C, Chen JL, Coravos A, Stern AD. Quantifying the use of connected digital products in clinical research. npj Digital Medicine. 2020 Apr 3;3(1):1–5.

⁶ Inan OT, Tenaerts P, Prindiville SA, Reynolds HR, Dizon DS, Cooper-Arnold K, et al. Digitizing clinical trials. npj Digital Medicine. 2020 Jul 31;3(1):1–7.

⁷ Erridge S, Majeed A, Sodergren M. Virtual trials: looking beyond covid-19 [Internet]. the bmj opinion. 2020 Jul 06. [cited 2020 Nov 06]. Available from: https://blogs.bmj.com/bmj/2020/07/06/virtual-trials-looking-beyond-covid-19/

⁸ COVID-19 Emergency Declaration Blanket Waivers for Health Care Providers [Internet]. Centers for Medicare & Medicaid Services. [accessed 2020 Aug 24]. Available from: https://www.cms.gov/files/document/summary-covid-19-emergency-declaration-waivers.pdf

⁹ Mecklai K, Smith N, Stern AD, and Kramer DB. Remote Patient Monitoring — Overdue or Overused? [Internet]. N Engl J Med Perspective. 2021 Apr 10;384:1384-1386.

10 Download AACT Database. Clinical Trials Transformation Initiative. [downloaded on 2020 October 21]. Available from: <u>https://aact.ctti-clinicaltrials.org/</u>


¹¹ 121 STAT. 904 PUBLIC LAW 110-85--SEPT. 27, 2007 [Internet]. Available from: https://www.govinfo.gov/content/pkg/PLAW-110publ85/pdf/PLAW-110publ85.pdf#page=82

¹²Clinical Trials [Internet]. International Committee of Medical Journal Editors. [cited 2020 Oct 21]. Available from: <u>http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html</u>

¹³ Glossary of Common Site Terms [Internet]. ClinicalTrials.gov. [cited 2020 Oct 21]. Available from: https://clinicaltrials.gov/ct2/about-studies/glossary

¹⁴ Recruitment Status Description [Internet]. ClinicalTrials.gov. [accessed 2020 Oct 21]. https://clinicaltrials.gov/ct2/help/glossary/recruitment-status. ¹⁵ Seema Verma. Early Impact of CMS Expansion of Medicare Telehealth During COVID-19
 [Internet]. Health Affairs Blog. 2020 [cited 2020 Oct 21]. Available from: /do/10.1377/hblog20200715.454789/full

tor beer terien only




Source: Authors' analysis of ClinicalTrials.gov data.

88

₿9 40

41

Notes: The Pre-Period and Post-Period analysis windows include the 10 months before and after the COVID-19 pandemic onset. Percentages on the left and right represent the average For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml percentage of trials using connected digital products during the pre- and post-period, respectively. Asterisks indicate statistical significance in the mean difference between the pre-and post-periods using two-sided proportion tests.



Notes: "Pre-period" and "Post-period" refer to the ten months immediately before and after COVID-19 onset in the US. March and April 2020 are excluded because policy changes and guidance documents were issued during that time. Trials started in the post-period are divided into "COVID" trials and "non-COVID" trials based on their diagnoses in the

ClinicalTrials.gov conditions label. Asterisks indicate statistical significance in the mean difference between the pre- and post-periods using two-sided proportion tests.

BMJ Open

Supplementary Materials

(To accompany the manuscript *The use of connected digital products in clinical research following the COVID-19 pandemic: a comprehensive analysis of clinical trials)*

Additional Details on Methods Used to Create and Validate Search Term Algorithm for

Identification of Connected Digital Products

Below is the complete set of the 140 search terms adapted from the list used in Marra, et al. 2020 to include additional terms related to telehealth delivery. These terms were used to identify a clinical trial as using a connected digital product (CDP). The research team used an automated algorithm to search for each term in several relevant ClinicalTrials.gov fields, such as "official title", "brief summary", "detailed description", "interventions", "study arms", and "outcome measures."

To confirm accuracy of the search algorithm, a random number generator was used to select 500 trials (250 from the pre-period and 250 from the post-period) for manual review. Of the 500 reviewed by the research team, 2 false positives were found, suggesting sensitivity of the search algorithm to be >99%. False positives were trials where a search term was found by the algorithm but manual review discovered that the CDP was not used to support remote monitoring or telehealth delivery. Within the 500 reviewed, there were also 4 false negatives identified, which were trials where the algorithm did not identify a CDP but manual review found one was used. This suggests algorithm specificity to be ~99%.

To alleviate incomplete data concerns arising from trial registration delays, we downloaded ClinicalTrials.gov records with trial start dates occurring between May 1, 2019 through February 28, 2021 from <u>https://aact.ctti-clinicaltrials.org/</u> on April 2, 2020, allowing 5 weeks for trial sponsors to retroactively register studies.

Search Term List:

1.	accuchek	31.	exercise bracelet	61.	ncapp
2.	actigraph	32.	facebook	62.	newsfeed
3.	activity monitor	33.	fall risk bracelet	63.	non-contact ecg
4.	aim covid-19 app	34.	fitbit	64.	online class
5.	amazon alexa	35.	freestyle libre	65.	online coaching
6.	app-based practice	36.	gamification	66.	online contact
7.	apple watch	37.	garmin	67.	online daily diary
8.	awareness bracelet	38.	google	68.	online exercise
9.	biosensor	39.	handheld manometer	69.	online fall detection system
10.	biovitals	40.	hand-held spirometer	70.	on-line forum
11.	brave program	41.	health app	71.	on-line group
12.	cct game	42.	hear glue ear app	72.	online intervention
13.	chat-based support	43.	holter monitor	73.	online learning
14.	collected online	44.	home pulse oximeter	74.	online meeting
15.	conducted entirely online	45.	hwa watch	75.	online mindfulness
16.	continuous glucose monitor	46.	hydration sensor	interven	
17.	covid-19 symptom tracker	47.	i-neb	76.	online platform
18.	dexcom	48.	ICOPE App	77.	online questionnaire
19.	digital app	49.	intelligent pulse oximeter	78. question	online self-administered
20.	digital biomarker	50.	internet	79.	online self-completed
21.	digital camera	51.	ipad	questionnaire	nnaire
22.	digital cardiac counseling	52.	iphone	80.	online support
23.	digital counseling	53.	meditation app	81.	online survey
24.	digital data collection	54.	mhealth	82.	online trial
25.	digital therapeutic	55.	mindfulness app	83.	online yoga
26.	digital video camera	56.	minimed	84.	phone app
27.	e-learning	57.	miro	85.	phone call
28.	electronic data collection	58.	mobile app	86.	phone interview
29.	electronic patient journal	59.	mobile device	87.	post online
30.	electronic questionnaire	60.	movehero	88.	qualtrics

BMJ Open

2				
3	89.	redcap	120.	video chat
4 5	90.	reminder bracelet	121.	video communication
6 7	91.	remote assessment	122.	video consultation
8	92.	remote consultation	123.	video encounters
9 10	93.	remote mindfulness session	124.	video observation
11 12	94.	remote monitoring	125.	videoconferencing
12	95.	secure electronic ecrf	126.	videophone call
14 15				-
16	96.	skype	127.	virtual check-in
17	97.	sleep sense	128.	virtual care at home
18 19	98.	smart bracelet	129.	virtual clinic
20	99.	smart care vip bracelet	130.	virtual group intervention
21 22	100.	smartpill	131.	virtual reality
23	101.	smart tv	132.	virtual visit
24 25				
26	102.	smartphone	133.	watchpat
27 28	103.	smartwatch	134.	wearable
29	104.	social media	135.	web-application
30 31	105.	stop touching your face	136.	web based
32	progran	n	137.	webex
33	106.	study website	138.	wechat
34 35	107.	tablet-based game		
36	108.	teleconference	139.	whatsapp
37 38	109.	teleconsultation	140.	zoom
39				
40 41	110.	telehealth		
42	111.	telemedicine		
43 44	112.	telephone		
45	113.	telephone coaching		
46 47	114.	telerehabilitation		
48 49	115.	text message		
49 50	116.	thermal sensor chip		
51 52	117.	vibrolung		
52 53		-		
54	118.	video-based		
55 56	119.	video call		
57				
58 59				
55		For peer review on	ly_http:	//hmiopen.hmi.com/site/about/quidelines.yhtm

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Supplemental Analysis of Trials Conducted within the United States

As a robustness check, we removed trials conducted outside of the United States because the guidance encouraging virtual trials was issued by the U.S. FDA. We determine the trial location using the "location countries" field in the ClinicalTrials.gov record. Approximately 32% (15,627/49,482) of trials started during the study period (between May 1, 2019 and February 28,2021; March & April 2020 excluded) had a U.S. site listed, 11% had no country listed, and the remaining 57% were conducted in other countries. Though we find a somewhat higher rate of CDP adoption among U.S. trials (between 15.7-24.3% per month), the average increase in CDP usage among U.S. trials following the pandemic onset was the same as the average seen for all trials in the sample (a 1.7 percentage point increase from pre-period to post-period) [Figure 3].

